Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Wong on Recent Developments in AL Amyloidosis

September 10th 2020

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain

September 10th 2020

Kami J. Maddocks, MD, discusses the utility of BTK inhibitors in B-cell malignancies, challenges that are still faced in the space, and areas primed for additional development.

FDA Approval Sought for Subcutaneous Daratumumab in AL Amyloidosis

September 10th 2020

A supplemental biologics license application has been submitted to the FDA for daratumumab plus hyaluronidase-fihj for the treatment of patients with amyloid light chain amyloidosis.

Ofatumumab to Be Available Through a Patient Access Program for CLL

September 10th 2020

Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.

CLR 131 Elicits Clinically Meaningful Responses in Triple-Class Refractory Myeloma

September 9th 2020

The first-in-class radioiodinated phospholipid drug conjugate CLR 131 elicited a clinically meaningful overall response rate of 40% in patients with triple-class refractory multiple myeloma who received a total administered dose of 60 mCi or greater.

Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Transplantation Using Haploidentical Donors Outperforms Matched Sibling Donors in MRD+ ALL

September 9th 2020

Haploidentical donor transplantation led to stronger anti-leukemia activity compared with matched sibling donor transplantation in transplant-eligible patients with minimal residual disease–positive acute lymphoblastic leukemia.

Sekeres Sheds Light on Promising Activity With Pevonedistat/Azacitidine in Higher-Risk MDS, Low-Blast AML

September 9th 2020

Mikkael A. Sekeres, MD, highlights findings from a phase 2 study that evaluated the combination of pevonedistat and azacitidine in higher-risk MDS, CML, and LB AML, and the next steps for research.

Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm

September 9th 2020

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma

September 8th 2020

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Basiliximab Elicits High Response Rates After Haploidentical HSCT in Pediatric Acute GVHD

September 8th 2020

Basiliximab proved to be an effective second-line treatment option for pediatric patients with steroid-refractory acute graft-versus-host disease that developed following haploidentical hematopoietic stem cell transplantation.

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

September 8th 2020

Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.

Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL

September 7th 2020

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.

Ruxolitinib Demonstrates Durable Responses in Steroid-Refractory aGVHD

September 4th 2020

Ruxolitinib continued to elicit a significantly higher overall response rate compared with best available therapy at day 28 in patients with steroid-refractory acute graft-versus-host disease.

Blinatumomab Represents a New Standard of Care in Pediatric High-Risk First-Relapse ALL

September 2nd 2020

Blinatumomab monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant resulted a significant improvement in event-free survival and a lower risk of recurrence in children with high-risk B-cell precursor–acute lymphoblastic leukemia.

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

September 2nd 2020

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Belumosudil Continues to Elicit Statistically Significant Responses in cGVHD

September 2nd 2020

The orally available ROCK2 selective inhibitor belumosudil continues to elicit clinically meaningful overall response rates in patients with chronic graft-versus-host disease (cGVHD) who have received ≥2 prior lines of systemic therapy

Dr. Maddocks on Emerging Therapies in Follicular Lymphoma

September 1st 2020

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

FDA Approves Oral Azacitidine for Acute Myeloid Leukemia

September 1st 2020

The FDA has approved oral azacitidine for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy who are not able to complete intensive curative therapy.